Monte Rosa Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary

Monte Rosa Therapeutics

06/08/2026 15:32

Monte Rosa Therapeutics, Inc. GLUE.OQ reported a quarterly adjusted loss of 43 cents​​ per share for the quarter ended June 30, lower than the same quarter last year, when the company reported EPS of -15 cents.  The mean expectation of seven analysts for the quarter was for a loss of 38 cents per share. Wall Street expected results to range from -53 cents to 4 cents per share.
Revenue fell 61.3% to $8.97 million from a year ago; analysts expected $5.52 million. 
Monte Rosa Therapeutics, Inc.'s reported EPS for the quarter was a loss of 43 cents​.
The company reported a quarterly loss of $43.4 million.
Monte Rosa Therapeutics, Inc. shares had fallen by 35.5% this quarter and lost 0.4% so far this year.
FORECAST CHANGES
The mean earnings estimate of analysts had risen by about 2.2% in the last three months.​ 
In the last 30 days, there have been no negative revisions of earnings estimates
RECOMMENDATIONS
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy" 
Wall Street's median 12-month price target for Monte Rosa Therapeutics, Inc. is $29.00, about 46.2% above its last closing price of $15.61
This summary was machine generated from LSEG data August 6 at 02:32 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
QUARTER ENDING
ESTIMATE 
ACTUAL
BEAT, MET, MISSED
Jun. 30 2026 
-0.38
-0.43
Missed
Mar. 31 2026 
-0.38
-0.45
Missed
Dec. 31 2025 
-0.35
-0.56
Missed
Sep. 30 2025 
-0.37
-0.33
Beat